EXHIBIT "WITN3094001/9"

This is the exhibit marked "WITN3094001/1" referred to in the witness statement of Debra Anne Pollard dated 7 May 2019

Royal Free Hampstead NHS
NHS Trust

Royal Free Hospital
Pond Street
London NW3 2QG

Tel 020 7794 0500
Fax 020 7830 2468

HAEMOPHILIA CENTRE & HAEMOSTASIS UNIT
Director: Professor Christine A Lee MA MD DSc(Med) FRCP FRCPath
Senior Lecturer: Dr GRO-D D PhD FRCP FRCPath
Consultant: Dr MB MRCP MRCPath

Tele No: GRO-C
Fax No:
E-mail:

CAL/RM
5th April, 2001

Mr Nicholas Ryness Hirsch

GRO-C

Dear Mr Hirsch

EFFECTS OF BAYER CEASING TO RELEASE RECOMBINANT FACTOR VIII

The Pharmaceutical Company Bayer have suspended product release for Koganate FS and Aventis-Behring'S Helixate. The information is that the suspension will be for 90 days followed by 45 days for product release in Europe. This results in a short fall of recombinant factor VIII in United Kingdom of approximately 6.1 million units per month. At the Royal Free children are treated with recombinant factor VIII for prophylaxis and we use approximately half a million units per month. It is therefore, likely that even with some modification of their prophylactic regimen some children may have to change back to plasma derived product and thus there will be a greater demand for this. As you can see from the enclosed paper at a meeting of the UKHCDO Advisory Committee certain recommendations were made in order to manage the shortage through the next few months. It is therefore, likely that the amount of plasma derived factor VIII that can be released for home treatment will be reduced and it would be helpful if you could review your treatment and see if any reduction in amount could be made in the short term without causing excessive break through bleeding.

Yours sincerely

Christine A Lee
Professor of Haemophilia